SUO 2022
SUO 2022
Advertisement
Patrick DalySUO 2022 | December 2, 2022
Increasing BMI in prostate cancer was associated with Gleason Grade Group 3 and pT3 stage PZ tumors and larger TZ tumors.
Read More
Patrick DalySUO 2022 | December 2, 2022
18F-rhPSMA-7.3 showed high sensitivity for detecting pelvic lymph node metastases in newly diagnosed prostate cancer.
Patrick DalySUO 2022 | December 2, 2022
Outpatient RARP showed significant cost savings and patient satisfaction and safety comparable with inpatient procedures.
Patrick DalySUO 2022 | December 2, 2022
Researchers found baseline testosterone levels had no significant impact on relugolix treatment outcomes in prostate cancer.
Patrick DalySUO 2022 | December 2, 2022
Up to 11% of patients had incontinence 1 year after radical prostatectomy, but salvage treatment rate was low, study finds.
Patrick DalySUO 2022 | December 2, 2022
Androgen deprivation therapy for prostate cancer may be associated with increased risks for neurocognitive disorders.
Patrick DalySUO 2022 | December 2, 2022
Only a small proportion of patients with prostate cancer recurrence received follow-up salvage treatment, according to data.
Patrick DalySUO 2022 | December 2, 2022
Weight gain and obesity were correlated with more cardiovascular and all-cause mortality, but not prostate cancer survival.
Patrick DalySUO 2022 | November 30, 2022
Patients who recovered from postprostatectomy incontinence started physical therapy earlier than patients who did not.
Patrick DalySUO 2022 | November 30, 2022
A study suggested patients with prostate cancer on active surveillance could benefit from additional systematic biopsies.
Patrick DalySUO 2022 | November 30, 2022
Evidence supported standard-of-care treatments and opposed cryosurgery in patients with prostate cancer and HIV or AIDS.
Patrick DalySUO 2022 | November 30, 2022
Study found extracellular vesicle testing reduced MRI false positives in patients with high PSA, sparing confirmatory biopsy.
Advertisement
Advertisement
Advertisement